Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

EP: 1.Clinical Scenario I: 68-yr Old Man with Early Relapse MM

EP: 2.Clinical Insights on Next Treatment Approach Steps

EP: 3.Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

EP: 4.Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

EP: 5.Overview of CAR T-cell Therapy Options in R/R MM

Now Viewing

EP: 6.Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

EP: 7.Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

EP: 8.Clinical Insights on the Patient Presentation & Treatment Course

EP: 9.Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

EP: 10.Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

EP: 11.Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

Video content above is prompted by the following:

• As the myeloma treatment landscape constantly evolves, where do you see selinexor fitting in? How might the future use of selinexor change?
• What are some key takeaways you can offer community colleagues? How can community oncologists partner with academic clinicians for patient identification and treatment?